Sonofii
Sonofii is an early-stage life science company focused on advancing the treatment of soft tissue infections and chronic wounds. Leveraging a proprietary dual dynamic technology, the company targets antibiotic-resistant and biofilm-associated infections to accelerate healing while aiming to lower healthcare costs. The solution is investigational and currently pre-FDA approval, demonstrated in clinical trials to offer high infection resolution rates, including for MDR pathogens like MRSA.
Industries
N/A
Products
A system combining localized antibiotic infusion with ultrasonic dispersion to disrupt biofilm and deliver high concentrations of antibiotics directly at infection sites. The technology aims to resolve chronic or resistant soft tissue infections and accelerate wound healing. Investigational and pre-FDA approval.
A system combining localized antibiotic infusion with ultrasonic dispersion to disrupt biofilm and deliver high concentrations of antibiotics directly at infection sites. The technology aims to resolve chronic or resistant soft tissue infections and accelerate wound healing. Investigational and pre-FDA approval.
Expertise Areas
- Chronic wound management
- Biofilm-related infection treatment
- Antimicrobial resistance mitigation
- Localized drug delivery
Key Technologies
- Ultrasound-assisted drug delivery
- Biofilm targeting technology
- Localized antibiotic infusion
News & Updates
Reference for understanding clinical approaches to biofilms in chronic wounds.
Addresses the worldwide economic significance of biofilm-associated infections.
Discusses wound healing statistics and outcomes.
Explores why biofilm presence leads to antibiotic resistance in infections.
Quantifies prevalence of biofilm in chronic versus acute wounds.
Queen et al. What’s the true costs of wounds faced by different healthcare systems around the world?
Editorial discussing the financial burden of chronic wounds.
Reference for understanding clinical approaches to biofilms in chronic wounds.
Addresses the worldwide economic significance of biofilm-associated infections.
Discusses wound healing statistics and outcomes.
Explores why biofilm presence leads to antibiotic resistance in infections.
Quantifies prevalence of biofilm in chronic versus acute wounds.
Queen et al. What’s the true costs of wounds faced by different healthcare systems around the world?
Editorial discussing the financial burden of chronic wounds.